Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab
Combined analysis of PD-L1 expression in malignant and tumor-infiltrating cells can be a promising biomarker for the prognosis of HCC patients treated with AB.
Authors
- Ji Won Han (ORCID: https://orcid.org/0000-0003-1456-1450)
- Ji Hoon Kim (ORCID: https://orcid.org/0000-0003-3924-0434)
- Joon‐Il Choi (ORCID: https://orcid.org/0000-0003-0018-8712)
- Pil Soo Sung (ORCID: https://orcid.org/0000-0002-5780-9607)
- Jeong Won Jang (ORCID: https://orcid.org/0000-0003-3255-8474)
- Young Chul Yoon (ORCID: https://orcid.org/0000-0002-5341-2370)
- Jong Young Choi (ORCID: https://orcid.org/0000-0001-7833-0307)
- Jae-Sung Yoo (ORCID: https://orcid.org/0009-0005-7875-6486)
- Jae Jun Lee (ORCID: https://orcid.org/0000-0002-5418-500X)
- Bohyun Kim (ORCID: https://orcid.org/0000-0003-1157-415X)
- Keungmo Yang (ORCID: https://orcid.org/0009-0005-0922-6588)
- Dong Yeup Lee (ORCID: https://orcid.org/0000-0003-1545-2627)
Institutions
- Kyungpook National University (KR)
- The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.3389/fimmu.2024.1506355
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- National Research Foundation
- Ministry of Health and Welfare
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea